遺伝子改変T細胞の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR2190)
◆英語タイトル:Global Engineered T Cells Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR2190
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:96
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥499,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥748,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、遺伝子改変T細胞の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(腫瘍浸潤リンパ球、T細胞受容体{TCR}、キメラ抗原受容体(CAR))、用途別市場規模(病院、がん研究センター、クリニック)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・遺伝子改変T細胞の市場動向
・企業の競争状況、市場シェア
・遺伝子改変T細胞の種類別市場規模(腫瘍浸潤リンパ球、T細胞受容体{TCR}、キメラ抗原受容体(CAR))
・遺伝子改変T細胞の用途別市場規模(病院、がん研究センター、クリニック)
・遺伝子改変T細胞の北米市場規模2016-2027(アメリカ、カナダ)
・遺伝子改変T細胞の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・遺伝子改変T細胞のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・遺伝子改変T細胞の中南米市場規模2016-2027(メキシコ、ブラジル)
・遺伝子改変T細胞の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Autolus Limited、Bellicum Pharmaceuticals、Cells Medica、Elli Lilly and Company、Gilead Sciences、Juno Therapeutics、Novartis、Oxford Biomedica、Pfizer、Precision Bioscience、Redmile Group、Seeking Alpha、Unum Therapeutics)
・結論
【レポートの概要】

Market Analysis and Insights: Global Engineered T Cells Market
The global Engineered T Cells market size is projected to reach US$ 1368.4 million by 2026, from US$ 263.2 million in 2019, at a CAGR of 26.4% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Engineered T Cells market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Engineered T Cells market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Engineered T Cells market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Engineered T Cells market.

Global Engineered T Cells Scope and Market Size
Engineered T Cells market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Engineered T Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Tumor Infiltrating Lymphocytes
T Cell Receptor {TCR}
Chimeric Antigen Receptor (CAR)

Segment by Application
Hospitals
Cancer Research Centers
Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Elli Lilly and Company
Gilead Sciences

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Engineered T Cells Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tumor Infiltrating Lymphocytes
1.2.3 T Cell Receptor {TCR}
1.2.4 Chimeric Antigen Receptor (CAR)
1.3 Market by Application
1.3.1 Global Engineered T Cells Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.3.4 Clinics
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Engineered T Cells Market Perspective (2016-2027)
2.2 Engineered T Cells Growth Trends by Regions
2.2.1 Engineered T Cells Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Engineered T Cells Historic Market Share by Regions (2016-2021)
2.2.3 Engineered T Cells Forecasted Market Size by Regions (2022-2027)
2.3 Engineered T Cells Industry Dynamic
2.3.1 Engineered T Cells Market Trends
2.3.2 Engineered T Cells Market Drivers
2.3.3 Engineered T Cells Market Challenges
2.3.4 Engineered T Cells Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Engineered T Cells Players by Revenue
3.1.1 Global Top Engineered T Cells Players by Revenue (2016-2021)
3.1.2 Global Engineered T Cells Revenue Market Share by Players (2016-2021)
3.2 Global Engineered T Cells Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Engineered T Cells Revenue
3.4 Global Engineered T Cells Market Concentration Ratio
3.4.1 Global Engineered T Cells Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Engineered T Cells Revenue in 2020
3.5 Engineered T Cells Key Players Head office and Area Served
3.6 Key Players Engineered T Cells Product Solution and Service
3.7 Date of Enter into Engineered T Cells Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Engineered T Cells Breakdown Data by Type
4.1 Global Engineered T Cells Historic Market Size by Type (2016-2021)
4.2 Global Engineered T Cells Forecasted Market Size by Type (2022-2027)

5 Engineered T Cells Breakdown Data by Application
5.1 Global Engineered T Cells Historic Market Size by Application (2016-2021)
5.2 Global Engineered T Cells Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Engineered T Cells Market Size (2016-2027)
6.2 North America Engineered T Cells Market Size by Type
6.2.1 North America Engineered T Cells Market Size by Type (2016-2021)
6.2.2 North America Engineered T Cells Market Size by Type (2022-2027)
6.2.3 North America Engineered T Cells Market Size by Type (2016-2027)
6.3 North America Engineered T Cells Market Size by Application
6.3.1 North America Engineered T Cells Market Size by Application (2016-2021)
6.3.2 North America Engineered T Cells Market Size by Application (2022-2027)
6.3.3 North America Engineered T Cells Market Size by Application (2016-2027)
6.4 North America Engineered T Cells Market Size by Country
6.4.1 North America Engineered T Cells Market Size by Country (2016-2021)
6.4.2 North America Engineered T Cells Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Engineered T Cells Market Size (2016-2027)
7.2 Europe Engineered T Cells Market Size by Type
7.2.1 Europe Engineered T Cells Market Size by Type (2016-2021)
7.2.2 Europe Engineered T Cells Market Size by Type (2022-2027)
7.2.3 Europe Engineered T Cells Market Size by Type (2016-2027)
7.3 Europe Engineered T Cells Market Size by Application
7.3.1 Europe Engineered T Cells Market Size by Application (2016-2021)
7.3.2 Europe Engineered T Cells Market Size by Application (2022-2027)
7.3.3 Europe Engineered T Cells Market Size by Application (2016-2027)
7.4 Europe Engineered T Cells Market Size by Country
7.4.1 Europe Engineered T Cells Market Size by Country (2016-2021)
7.4.2 Europe Engineered T Cells Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Engineered T Cells Market Size (2016-2027)
8.2 Asia-Pacific Engineered T Cells Market Size by Type
8.2.1 Asia-Pacific Engineered T Cells Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Engineered T Cells Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Engineered T Cells Market Size by Type (2016-2027)
8.3 Asia-Pacific Engineered T Cells Market Size by Application
8.3.1 Asia-Pacific Engineered T Cells Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Engineered T Cells Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Engineered T Cells Market Size by Application (2016-2027)
8.4 Asia-Pacific Engineered T Cells Market Size by Region
8.4.1 Asia-Pacific Engineered T Cells Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Engineered T Cells Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Engineered T Cells Market Size (2016-2027)
9.2 Latin America Engineered T Cells Market Size by Type
9.2.1 Latin America Engineered T Cells Market Size by Type (2016-2021)
9.2.2 Latin America Engineered T Cells Market Size by Type (2022-2027)
9.2.3 Latin America Engineered T Cells Market Size by Type (2016-2027)
9.3 Latin America Engineered T Cells Market Size by Application
9.3.1 Latin America Engineered T Cells Market Size by Application (2016-2021)
9.3.2 Latin America Engineered T Cells Market Size by Application (2022-2027)
9.3.3 Latin America Engineered T Cells Market Size by Application (2016-2027)
9.4 Latin America Engineered T Cells Market Size by Country
9.4.1 Latin America Engineered T Cells Market Size by Country (2016-2021)
9.4.2 Latin America Engineered T Cells Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Engineered T Cells Market Size (2016-2027)
10.2 Middle East & Africa Engineered T Cells Market Size by Type
10.2.1 Middle East & Africa Engineered T Cells Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Engineered T Cells Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Engineered T Cells Market Size by Type (2016-2027)
10.3 Middle East & Africa Engineered T Cells Market Size by Application
10.3.1 Middle East & Africa Engineered T Cells Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Engineered T Cells Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Engineered T Cells Market Size by Application (2016-2027)
10.4 Middle East & Africa Engineered T Cells Market Size by Country
10.4.1 Middle East & Africa Engineered T Cells Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Engineered T Cells Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Autolus Limited
11.1.1 Autolus Limited Company Details
11.1.2 Autolus Limited Business Overview
11.1.3 Autolus Limited Engineered T Cells Introduction
11.1.4 Autolus Limited Revenue in Engineered T Cells Business (2016-2021)
11.1.5 Autolus Limited Recent Development
11.2 Bellicum Pharmaceuticals
11.2.1 Bellicum Pharmaceuticals Company Details
11.2.2 Bellicum Pharmaceuticals Business Overview
11.2.3 Bellicum Pharmaceuticals Engineered T Cells Introduction
11.2.4 Bellicum Pharmaceuticals Revenue in Engineered T Cells Business (2016-2021)
11.2.5 Bellicum Pharmaceuticals Recent Development
11.3 Cells Medica
11.3.1 Cells Medica Company Details
11.3.2 Cells Medica Business Overview
11.3.3 Cells Medica Engineered T Cells Introduction
11.3.4 Cells Medica Revenue in Engineered T Cells Business (2016-2021)
11.3.5 Cells Medica Recent Development
11.4 Elli Lilly and Company
11.4.1 Elli Lilly and Company Company Details
11.4.2 Elli Lilly and Company Business Overview
11.4.3 Elli Lilly and Company Engineered T Cells Introduction
11.4.4 Elli Lilly and Company Revenue in Engineered T Cells Business (2016-2021)
11.4.5 Elli Lilly and Company Recent Development
11.5 Gilead Sciences
11.5.1 Gilead Sciences Company Details
11.5.2 Gilead Sciences Business Overview
11.5.3 Gilead Sciences Engineered T Cells Introduction
11.5.4 Gilead Sciences Revenue in Engineered T Cells Business (2016-2021)
11.5.5 Gilead Sciences Recent Development
11.6 Juno Therapeutics
11.6.1 Juno Therapeutics Company Details
11.6.2 Juno Therapeutics Business Overview
11.6.3 Juno Therapeutics Engineered T Cells Introduction
11.6.4 Juno Therapeutics Revenue in Engineered T Cells Business (2016-2021)
11.6.5 Juno Therapeutics Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Engineered T Cells Introduction
11.7.4 Novartis Revenue in Engineered T Cells Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Oxford Biomedica
11.8.1 Oxford Biomedica Company Details
11.8.2 Oxford Biomedica Business Overview
11.8.3 Oxford Biomedica Engineered T Cells Introduction
11.8.4 Oxford Biomedica Revenue in Engineered T Cells Business (2016-2021)
11.8.5 Oxford Biomedica Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Engineered T Cells Introduction
11.9.4 Pfizer Revenue in Engineered T Cells Business (2016-2021)
11.9.5 Pfizer Recent Development
11.10 Precision Bioscience
11.10.1 Precision Bioscience Company Details
11.10.2 Precision Bioscience Business Overview
11.10.3 Precision Bioscience Engineered T Cells Introduction
11.10.4 Precision Bioscience Revenue in Engineered T Cells Business (2016-2021)
11.10.5 Precision Bioscience Recent Development
11.11 Redmile Group
11.11.1 Redmile Group Company Details
11.11.2 Redmile Group Business Overview
11.11.3 Redmile Group Engineered T Cells Introduction
11.11.4 Redmile Group Revenue in Engineered T Cells Business (2016-2021)
11.11.5 Redmile Group Recent Development
11.12 Seeking Alpha
11.12.1 Seeking Alpha Company Details
11.12.2 Seeking Alpha Business Overview
11.12.3 Seeking Alpha Engineered T Cells Introduction
11.12.4 Seeking Alpha Revenue in Engineered T Cells Business (2016-2021)
11.12.5 Seeking Alpha Recent Development
11.13 Unum Therapeutics
11.13.1 Unum Therapeutics Company Details
11.13.2 Unum Therapeutics Business Overview
11.13.3 Unum Therapeutics Engineered T Cells Introduction
11.13.4 Unum Therapeutics Revenue in Engineered T Cells Business (2016-2021)
11.13.5 Unum Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 遺伝子改変T細胞の世界市場規模・現状・予測2021年-2027年(Global Engineered T Cells Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。